ALT 803

Drug Profile

ALT 803

Alternative Names: ALT-803; IL-15N72D:IL-15RαSu/Fc fusion protein complex

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Altor BioScience Corporation; NantKwest
  • Developer Altor BioScience Corporation; University of Minnesota; University of South Carolina
  • Class Antineoplastics; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants; Interleukin-15 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Bladder cancer; Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer
  • Phase I HIV infections; Malignant melanoma
  • Preclinical Bacterial infections
  • Phase Unknown Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 07 Dec 2016 Masonic Cancer Center, University of Minnesota plans a phase II trial for Acute myeloid leukaemia and Myelodysplastic syndromes (Prevention of relapse) in USA (SC) (NCT02989844)
  • 16 Nov 2016 NantKwest intends to file an IND application with the US FDA in USA for Solid tumours
  • 16 Nov 2016 NantKwest plans a pivotal transitional trial for Solid tumours (Combination therapy) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top